Mimetogen Pharmaceuticals USA, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary
- Established
- 2009-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.mimetogen.com
Efficacy and Safety Evaluation of Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry Eye SyndromesDry Eye DiseaseKerato Conjunctivitis Sicca
- Interventions
- Drug: 5% Tavilermide ophthalmic solutionOther: Vehicle ophthalmic solution
- First Posted Date
- 2023-05-08
- Last Posted Date
- 2024-06-10
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 642
- Registration Number
- NCT05848128
- Locations
- 🇺🇸
Eye Associates of Fort Myers, Fort Myers, Florida, United States
🇺🇸Eye Consultants of Atlanta, Atlanta, Georgia, United States
🇺🇸Midwest Vision Research Foundation, Chesterfield, Missouri, United States
Tavilermide Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry EyeKeratoconjunctivitis Sicca
- Interventions
- Other: Placebo
- First Posted Date
- 2019-04-24
- Last Posted Date
- 2023-04-05
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 623
- Registration Number
- NCT03925727
- Locations
- 🇺🇸
Tavilermide Investigational Site, Kenosha, Wisconsin, United States
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye Disease
Phase 3
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2016-01-27
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT02665234
- Locations
- 🇺🇸
MIM-726 Investigational Site, Torrance, California, United States
A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Keratoconjunctivitis Sicca
- Interventions
- Drug: Placebo Ophthalmic Solution
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2019-08-16
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 429
- Registration Number
- NCT02634853
- Locations
- 🇺🇸
MIM-727 Investigational Site, Nashville, Tennessee, United States
A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
Phase 3
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: MIM-D3 Ophthalmic SolutionDrug: Vehicle
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 403
- Registration Number
- NCT01960010
- Locations
- 🇺🇸
MIM-725 Investigational Site, Memphis, Tennessee, United States
Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye
Phase 2
Completed
- Conditions
- Dry Eye
- Interventions
- Drug: MIM-D3 Ophthalmic SolutionDrug: Placebo Ophthalmic Solution
- First Posted Date
- 2010-12-09
- Last Posted Date
- 2019-08-19
- Lead Sponsor
- Mimetogen Pharmaceuticals USA, Inc.
- Target Recruit Count
- 150
- Registration Number
- NCT01257607
- Locations
- 🇺🇸
Ora, Inc., Andover, Massachusetts, United States
© Copyright 2025. All Rights Reserved by MedPath